CG Oncology, Inc. (CGON)
NASDAQ · Healthcare
CG Oncology, Inc. EBITDA 2023–2025
CG Oncology, Inc. annual/quarterly ebitda history and growth rate from 2023 to 2026. EBITDA stands for Earnings Before Interest, Taxes, Depreciation and Amortization. It is widely used as a measure of core operational profitability.
- CG Oncology, Inc. ebitda for the quarter ending March 31, 2026 was -65.5 M, a 55.40% increase year-over-year.
- CG Oncology, Inc. ebitda for the twelve months ending March 31, 2026 was -139.9 M.
- CG Oncology, Inc. annual ebitda for 2025 was -189.3 M, a 65.16% increase from 2024.
- CG Oncology, Inc. annual ebitda for 2024 was -114.6 M, a 106.80% increase from 2023.
- CG Oncology, Inc. annual ebitda for 2023 was -55.4 M.
EBITDA
ANNUAL · $B
QUARTERLY · $B
YEAR-OVER-YEAR GROWTH · %
CG Oncology, Inc. EBITDA — FAQ
CG Oncology, Inc. (CGON) ebitda over the last 3 years — annual and quarterly figures with year-over-year growth and charts.
Where can I see CGON's ebitda history?
The chart and table above show CG Oncology, Inc.'s ebitda by year and by quarter, including the growth rate.